Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet mai. 2011;43(5):429–35.

Article  CAS  Google Scholar 

Dustin ML, Olszowy MW, Holdorf AD, Li J, Bromley S, Desai N, et al. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell. 1998;94(5):667–77.

Article  PubMed  CAS  Google Scholar 

Kim JM, Wu H, Green G, Winkler CA, Kopp JB, Miner JH, et al. CD2-Associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science. 2003;300(5623):1298–300.

Article  PubMed  CAS  Google Scholar 

Gigante M, Pontrelli P, Montemurno E, Roca L, Aucella F, Penza R, et al. CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant juin. 2009;24(6):1858–64.

Article  CAS  Google Scholar 

Liu YX, Zhang AQ, Luo FM, Sheng Y, Wang CY, Dong Y, et al. Case report: a novel heterozygous mutation of CD2AP in a Chinese family with proteinuria leads to focal segmental glomerulosclerosis. Front Pediatr. 2021;9:687455.

Article  PubMed  PubMed Central  Google Scholar 

Takano T, Bareke E, Takeda N, Aoudjit L, Baldwin C, Pisano P, et al. Recessive mutation in CD2AP causes focal segmental glomerulosclerosis in humans and mice. Kidney Int. 2019;95(1):57–61.

Article  PubMed  CAS  Google Scholar 

Akilesh S, Koziell A, Shaw AS. Basic science meets clinical medicine: identification of a CD2AP-deficient patient. Kidney Int. 2007;72(10):1181–3.

Article  PubMed  CAS  Google Scholar 

Gubler MC. Podocyte differentiation and hereditary proteinuria/nephrotic syndromes. J Am Soc Nephrol. 2003;14(suppl_1):S22.

Article  PubMed  Google Scholar 

Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science. 1999;286(5438):312–5.

Article  PubMed  CAS  Google Scholar 

Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577–90.

Article  PubMed  PubMed Central  CAS  Google Scholar 

2024 Alzheimer’s disease facts and figures. Alzheimers Dement. 2024;20(5):3708‑821.

Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population Estimate of People with Clinical AD and Mild Cognitive Impairment in the United States (2020–2060). Alzheimers Dement déc. 2021;17(12):1966–75.

Article  Google Scholar 

Golde TE. Alzheimer’s disease – the journey of a healthy brain into organ failure. Mol Neurodegener. 2022;17:18.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tremblay C, François A, Delay C, Freland L, Vandal M, Bennett DA, et al. Association of neuropathological markers in the parietal cortex with antemortem cognitive function in persons with mild cognitive impairment and alzheimer disease. J Neuropathol Exp Neurol. 2017;76(2):70–88.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Han JW, Maillard P, Harvey D, Fletcher E, Martinez O, Johnson DK, et al. Association of vascular brain injury, neurodegeneration, amyloid, and cognitive trajectory. Neurology. 2020;95(19):e2622-34.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tremblay C, François A, Delay C, Freland L, Vandal M, Bennett DA, et al. Association of neuropathological markers in the parietal cortex with antemortem cognitive function in persons with mild cognitive impairment and alzheimer disease. J Neuropathol Exp Neurol févr. 2017;76(2):70–88.

Article  CAS  Google Scholar 

Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018;141(7):1917–33.

Article  PubMed  PubMed Central  Google Scholar 

Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512–27.

Article  PubMed  PubMed Central  CAS  Google Scholar 

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9–21.

Article  PubMed  Google Scholar 

Jucker M, Walker LC. Alzheimer’s disease: From immunotherapy to immunoprevention. Cell. 2023;186(20):4260–70.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Smith EE, Phillips NA, Feldman HH, Borrie M, Ganesh A, Henri-Bhargava A, et al. Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research. J Prev Alzheimers Dis. 2025;100068.

Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer’s disease drug development pipeline: 2024. Alzheimers Dement (N Y). 2024;10(2):e12465.

Article  PubMed  Google Scholar 

Mummery CJ, Börjesson-Hanson A, Blackburn DJ, Vijverberg EGB, De Deyn PP, Ducharme S, et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2023;29(6):1437–47.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cummings JL, Osse AML, Kinney JW. Alzheimer’s disease: novel targets and investigational drugs for disease modification. Drugs. 2023;83(15):1387–408.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Erichsen J, Craft S. Targeting immunometabolic pathways for combination therapy in Alzheimer’s disease. Alzheimers Dement (N Y). 2023;9(4):e12423.

Article  PubMed  Google Scholar 

Self WK, Holtzman DM. Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med sept. 2023;29(9):2187–99.

Article  CAS  Google Scholar 

Livingston G, Huntley J, Liu KY, Costafreda SG, Selbæk G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572–628.

Article  PubMed  Google Scholar 

Bergem AL, Engedal K, Kringlen E. The role of heredity in late-onset Alzheimer disease and vascular dementia A twin study. Arch Gen Psychiatry. 1997;54(3):264–70.

Article  PubMed  CAS  Google Scholar 

Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry févr. 2006;63(2):168–74.

Article  Google Scholar 

Raiha I, Kaprio J, Koskenvuo M, Rajala T, Sourander L. Alzheimer’s disease in Finnish twins. Lancet. 1996;347(9001):573–8.

Article  PubMed  CAS  Google Scholar 

Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20(1):68–80.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol sept. 2019;15(9):501–18.

Article  CAS  Google Scholar 

Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349–56.

Article  PubMed